If you click through a couple of screens, this is
Post# of 148158
(Total Views: 691)
Posted On: 08/22/2022 10:00:08 AM
If you click through a couple of screens, this is what you will find. Looks like Dr. Kelly will have an opportunity to discuss Leronlimab applications beyond NASH.
Driving Innovation in Patient Selection: Rethinking Inclusion & Exclusion Criteria
Time: 2:00 pm
Day: Day 2 Stream 2 PM
Details:
Investigating clinical trials for NASH in HIV-infected patients
Evaluating novel biomarker outcomes in NASH and considering comorbidities
Beyond NASH: driving studies in cardiovascular and metabolic disorders
Speakers:
Scott Kelly
Driving Innovation in Patient Selection: Rethinking Inclusion & Exclusion Criteria
Time: 2:00 pm
Day: Day 2 Stream 2 PM
Details:
Investigating clinical trials for NASH in HIV-infected patients
Evaluating novel biomarker outcomes in NASH and considering comorbidities
Beyond NASH: driving studies in cardiovascular and metabolic disorders
Speakers:
Scott Kelly
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼